<DOC>
	<DOCNO>NCT02551315</DOCNO>
	<brief_summary>This multicenter , prospective , observational cohort study ass bone difference woman men type 2 diabetes mellitus ( T2DM ) without fragility fracture .</brief_summary>
	<brief_title>Microarchitecture , Bone Strength Fracture Risk Type 2 Diabetes</brief_title>
	<detailed_description>Cross-sectional evaluation clinical , biochemical microstructural measure bone patient type 2 diabetes age-matched healthy control . Longitudinal assessment clinical , biochemical microstructural measure bone study participant without prevalent fragility fracture .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Fractures , Bone</mesh_term>
	<criteria>presence type 2 diabetes least 3 year ( history treatment type 2 diabetes ) immobility coexist metabolic bone disease comorbidities affect bone health previous treatment osteoporosis medication intake medication know affect bone metabolism ( e.g . steroid ) within 6 month prior enrolment thiazolidinedione use</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Intra-cortical pore volume</keyword>
	<keyword>HR-pQCT</keyword>
	<keyword>DXA</keyword>
	<keyword>bone mineral density</keyword>
	<keyword>bone turnover marker</keyword>
	<keyword>urinary pentosidine</keyword>
</DOC>